Regeneron Pharmaceuticals Inc (REGN)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	37,759,400	37,441,900	36,086,800	34,369,600	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500
Total stockholders’ equity	US$ in thousands	29,353,600	29,325,900	28,205,800	26,991,100	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000
Financial leverage ratio		1.29	1.28	1.28	1.27	1.27	1.29	1.28	1.28	1.29	1.29	1.32	1.32	1.36	1.37	1.42	1.48	1.56	1.59	1.59	1.30

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $37,759,400K ÷ $29,353,600K
= 1.29

Regeneron Pharmaceuticals Inc's financial leverage ratio has exhibited a gradual decrease from 1.30 as of March 31, 2020, to 1.29 as of December 31, 2024. The trend indicates that the company has been effectively managing its debt relative to its equity over the analyzed period. A lower financial leverage ratio suggests less reliance on debt financing, which can be viewed positively by investors and creditors as it could signify a lower financial risk for the company. Additionally, a decreasing leverage ratio may indicate improved financial stability and a stronger ability to meet debt obligations. However, it is important to further analyze other financial metrics in conjunction with the leverage ratio to gain a comprehensive understanding of Regeneron Pharmaceuticals Inc's overall financial health and performance.